*Can disruption at LAT1,2 be achieved through MITF (SLC7A8)
*Is ZFYVE16 a substantial target in Gastric cancers
*should we be monitoring IL-1 in patients with GERD
as a biomarker risk of Gastric cancer
*Inhibition of RFXAP in T cell leukemia,what could be the effect!
*Blocking TOM1 could help in disease where MITF is a driving force (Melanoma). Are activities at MITF the reason for short duration of BRAF inhibitors?
*What happens when you block CD28 in Ovarian cancer
*Is CD79 a floppase?
*Inhibition of BIRC7 will unleash Apoptosis and could be the way to win over Mutation in MITF
*Should patient with melanoma of the eye avoid Beta Blockers because of effect on the GPC1
*Beta blocker protective or inducer of cancer, what is the state of GPC1 and DAB2 in patient taking this drug
*Role of Beta blocker in Ovarian cancer (connection through DAB2)
*Are the LRP (s) the connection of Fatty food to carcinogenesis?
*Block TOM1 when giving BRAF inhibitor?
No comments:
Post a Comment